To examine the translational potential of using a PARP-1 inhibitor to treat the sequelae of hyperglycemia in humans, we used the NCI-H716 enteroendocrine cell line that is widely used to study human GLP-1-secretion, an important modulator of insulin production [25]. This evidence concerns the gene PARP1 and Hyperglycemia.